KRAS and breast cancer: NOP56 is significantly increased in KRAS-mutant non-small cell lung cancer, KRAS-mutant pancreatic cancer, KRAS-mutant colorectal cancer, Wilms tumor, diffuse large B-cell lymphoma, Myc-mutant Burkitt’s lymphoma, breast cancer, prostate cancer, and acute lymphoblastic leukemia (8, 9, 46–51).